glp-1 in obesity Targeting GLP-1, GIP & GCG and Type 2 Diabetes Research GLP-1 signaling pathway in obesity

We hypothesize that the drastic inhibition of GLP-1 secretion via the shutdown of the main pathway through the SSTRs-Gi axis is the primary cause of pasireotide-induced hyperglycemia

CV Protection in the EMPA-REG OUTCOME trial: a thrifty substrate hypothesis

The strongest evidence remains in metabolic outcomes

Additionally a meta-analysis found use of GLP-1RA was associated with higher risk of gallbladder and biliary disease with high doses for longer duration (113)

Stay well-hydrated, eat a balanced meal beforehand, and avoid scheduling donations during your medication adjustment phase when side effects like nausea may be more pronounced